Unlike hormone receptor-positive or HER2-positive breast cancers, TNBC lacks common therapeutic targets, such as estrogen receptors or HER2, limiting the effectiveness of conventional targeted therapies. The gene discussed is NR4A1; the disease is breast cancer.